REG - Nuformix PLC - Result of AGM

NuformixAnnouncement

25/08/2022 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220825:nRSY2682Xa&default-theme=true

RNS Number : 2682X  Nuformix PLC  25 August 2022

Nuformix plc

 

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing,  announces that
the Annual General Meeting of Nuformix plc was held earlier today and all
resolutions put to shareholders were duly passed and approved on a show of
hands at the meeting.  The results of the proxy voting position received in
advance of the meeting are reported below:

 

     Resolution                                                                  Ordinary/ Special  For                  Against             Total votes cast
                                                                                                    No. of votes  %      No. of votes  %
 1   To receive the annual report and accounts for the year ended 31 March 2022  Ordinary           150,018,268   100    0             0     150,018,268


 2   To approve the Remuneration Policy                                          Ordinary           149,469,749   99.86  217,007       0.14  149,686,756

 3   To re-appoint Julian Gilbert as a director                                  Ordinary           150,096,308   99.93  106,121       0.07  150,202,429

 4   To re-appoint s Madeleine Kennedy as a director                             Ordinary           150,096,308   99.93  106,121       0.07  150,202,429

 5   To re-appoint Jeffreys Henry Audit Limited as auditor                       Ordinary           150,096,308   99.93  106,121       0.07  150,202,429

 6   To authorise the Directors to determine the auditor's fees.                 Ordinary           149,295,087   99.40  907,342       0.60  150,202,429

 7   To authorise the Directors to allot shares.                                 Ordinary           146,859,280   97.78  3,331,149     2.22  150,190,429

 8   To authorise the Directors to disapply pre-emption rights.                  Special            146,905,107   97.81  3,285,322     2.19  150,190,429

 9   To authorise the Company to purchase its own shares.                        Special            150,139,861   99.93  112,568       0.07  150,252,429

 10  To authorise calling of a general meeting on 14 clear days' notice.         Special            150,102,429   99.93  100,000       0.07  150,202,429

 

A vote withheld is not a vote in law and is not counted in the calculation of
votes validly cast for or against a resolution.

The Company's issued share capital is 709,309,368 ordinary shares of £0.001
each.

Enquiries:

 

 Nuformix plc
 Dr Daniel Gooding, Executive Director             Via IFC Advisory

 Dr Julian Gilbert, Non-executive Chairman

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical and Phase
1-ready assets with potential for significant value and early licensing
opportunities.

 

For more information, please visit www.nuformix.com
(http://www.nuformix.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGXELFLLVLXBBV